Designed to balance
efficacy, safety, and tolerability1,2
FDA-approved eye drop
specifically designed for presbyopia.1,2
A daily treatment
for mild-to-moderate patients
with presbyopia.1,3
The first FDA-approved eye drop specifically designed for presbyopia.1,2 A daily treatment for patients with presbyopia.1,3
Delivered with pHastTM technology Rapidly adjusts to physiologic pH*4
*In vitro data. Clinical significance is unknown.
The pH range in the bottle is between 3.5 and 5.5.1
*In vitro data. Clinical significance is unknown. The pH range in the bottle is between 3.5 and 5.5.1
Improved near and intermediate vision without compromising
distance vision1,5
distance vision1,5
Primary endpoint was the proportion of patients gaining ≥3 lines in mesopic, high-contrast, binocular distance-corrected near visual acuity (DCNVA) without losing more than 1 line (5 letters) of corrected distance visual acuity (CDVA) with the same refractive correction at Day 30, Hour 3.1
Change from baseline in photopic, high-contrast, binocular distance-corrected intermediate visual acuity (DCIVA) at Day 30, Hour 3 was a prespecified secondary endpoint.5
VUITY® has a well-established safety and tolerability profile in clinical trials1
NEARLY 9/10
Trial participants [N=76] surveyed would ask their eye doctor for VUITY®†6
†Assessed by a survey in a subset of participants in the VUITY® arm of GEMINI 1 and GEMINI 2 studies.
Not an actual patient
What we heard from trial participants‡
Actual participants not shown.
“These eye drops provided me another option for how I manage my presbyopia.”
‡The GEMINI 1 and GEMINI 2 trials were double masked, and during the trials the participants did not know if they were on treatment or vehicle.
Actual participants not shown.
“These eye drops helped me to see up close without compromising my distance vision.”
‡The GEMINI 1 and GEMINI 2 trials were double masked, and during the trials the participants did not know if they were on treatment or vehicle.
Actual participants not shown.
“Taking an eye drop once daily is convenient.”
‡The GEMINI 1 and GEMINI 2 trials were double masked, and during the trials the participants did not know if they were on treatment or vehicle.
Actual participants not shown.
“I don’t always want to wear reading glasses and these drops don’t change my look.”
‡The GEMINI 1 and GEMINI 2 trials were double masked, and during the trials the participants did not know if they were on treatment or vehicle.
Actual participants not shown.
“I used my reading
glasses less.§”
‡The GEMINI 1 and GEMINI 2 trials were double masked, and during the trials the participants did not know if they were on treatment or vehicle.
§Use of reading glasses was not permitted at study visits during the trials.